Atlas Trials

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

Clinical trial NCT04762459 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT04762459
Sponsor
Chinese Academy of Medical Sciences
Status
ENROLLING_BY_INVITATION
Phase
Phase 3
Study type
INTERVENTIONAL
Non-small Cell Lung Carcinoma
Start date
2021-08-01
Primary completion
2026-05-01
Enrollment
606

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.